TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7835118
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage growth hormone (GH) co-administered with gonadotropin (Gn)
Study: 3293642
Drug: Adrenaline 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 0.2 ml (0.2 mg) with 5% lignocaine 2 ml in 7.5% dextrose
Study: 3293642
Drug: Adrenaline 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 0.4 ml with 5% lignocaine 2 ml in 7.5% dextrose
Study: 3293642
Drug: 5% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lignocaine 2 ml in 7.5% dextrose with physiological saline 1 ml
Study: 31838113
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy at 6 l/min for 6 to 12 hours
Study: 19950305
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment for fibromyalgia
Study: 17242147
Drug: Apricitabine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricitabine at 600 mg twice daily
Study: 17242147
Drug: Apricitabine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricitabine at 600 mg twice daily with lamivudine at 300 mg once daily
Study: 17242147
Drug: Lamivudine at
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine at 300 mg once daily
Study: 8009342
Drug: Oxytocin antagonist
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin antagonist [d(CH2)5, Tyr(Me)2, Orn8]-vasotocin
Study: 8009342
Drug: Opiate receptor-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opiate receptor-blocker naloxone
Study: 8009342
Drug: Oxytocin antagonist
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin antagonist
Study: 28059417
Drug: 22 g
Normalized name: Empty Carpuject 2 mL 22 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 g freeze‐dried highbush blueberry powder per day
Study: 28059417
Drug: 22 g
Normalized name: Empty Carpuject 2 mL 22 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 g placebo powder per day
Study: 19039454
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost (n=10)
Study: 14600698
Drug: Quantec‐E irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantec‐E irrigation pump with 12 mL of 5.25% NaOCl, followed by 6 mL EDTA 17%, and a final flush with 4 mL 5.25% NaOCl
Study: 8729158
Drug: Dermagraft (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermagraft (one piece applied weekly for 8 weeks)
Study: 30149850
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy
Study: 20237063
Drug: Zinc treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc treatment (20 mg/d for 10 days)
Study: 20237063
Drug: Zinc treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc treatment plus supplementation (10 mg/d for 3 months after initial treatment)
Study: 20237063
Drug: Zinc treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc treatment (ZT)
Study: 20237063
Drug: Zinc treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc treatment plus supplementation (ZT+S)
Study: 18537187
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 microg/kg/day for 5 days)
Study: 1451291
Drug: Topical isotretinoin
Normalized name: isotretinoin Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical isotretinoin 0.05%
Study: 6548348
Drug: Other anti-emetic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other anti-emetic drugs
Study: 29843553
Drug: Ferrous bis-glycinate
Normalized name: ferrous bis-glycinate HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous bis-glycinate tablets once daily for eight consecutive weeks
Study: 29843553
Drug: Ferrous glycine
Normalized name: Ferrous glycine sulfate
DrugBank: Ferrous glycine sulfate (DB14501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous glycine sulfate capsules once daily for eight consecutive weeks
Study: 29436624
Drug: Lou type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lou type equation for warfarin dosing
Study: 20179126
Drug: Multi-component physical
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component physical activity programme (n=297) including structured physical education lessons, additional lessons, daily activity breaks, and homework.
Study: 16351361
Drug: Response compatibility
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response compatibility processes (e.g., Implicit Association Test, affective priming with an evaluative decision task)
Study: 16351361
Drug: Stimulus compatibility
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulus compatibility processes (e.g., semantic priming with a lexical-decision task)
Study: 31366053
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g baru almonds (BARU)
Study: 26503312
Drug: N-acetylcysteine (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (240 mg/kg over 12 h)
Study: 24657122
Drug: MenACWY‐CRM booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY‐CRM booster dose
Study: 10072015
Drug: Adenosine (ADO)
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine (ADO) infusion (60 microg x kg(‐1) x min(‐1))
Study: 21775560
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (daily vitamin C 120 mg, β-carotene 6 mg, vitamin E 30 mg, selenium 100 μg, zinc 20 mg)
Study: 20023348
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (electrotherapy and lumbar strengthening exercises)
Study: 11686810
Drug: Ready-to-use Emdogain-gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-use Emdogain-gel
Study: 9542288
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of plethysmography, vibrometry, two point discrimination, and monofilament testing
Study: 3166942
Drug: Grenz rays
Normalized name: Ray Dol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grenz rays alone (4 Gy administered on six occasions at intervals of 1 week)
Study: 3166942
Drug: Grenz rays
Normalized name: Ray Dol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grenz rays combined with topical corticosteroid (betamethasone dipropionate)
Study: 25466700
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil 20 or 40 mg p.o. t.i.d. for 6 weeks
Study: 20886505
Drug: Single Pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Pulse treatment
Study: 20886505
Drug: Double Pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double Pulse treatment
Study: 8840852
Drug: Ibutilide (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (1.0 and 0.5 mg or 1.0 and 1.0 mg)
Study: 1531484
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg in fasting state
Study: 1531484
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg in nonfasting state
Study: 27341450
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg) combined with lidocaine
Study: 18729147
Drug: Internet delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet delivered cognitive behavior therapy combined with five group exposure sessions (ICBT+ exp)
Study: 12634652
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (oral regimens with treatment durations of > or =7 days)
Study: 3935853
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (general)
Study: 12634652
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (low-risk patients)
Study: 12634652
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (vaginal regimens)
Study: 12634652
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment in patients with preterm labor
Study: 8768849
Drug: Pyridostigmine (PD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (PD; 120 mg, orally)
Study: 8768849
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PD and Pirenzepine (PZP; 100 mg, orally)
Study: 6637785
Drug: Alpha-adrenergic blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-adrenergic blocker prazosin
Study: 30919809
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg intravenous tranexamic acid dissolved in 100 mL of saline (TXA group)
Study: 30919809
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of saline solution (placebo group)
Study: 17538537
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil containing parenteral nutrition (FO: Lipoplus: LCT40%-MCT50%-FO10%)
Study: 17538537
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (STD: Lipofundin medium‐chain triglyceride (MCT): long‐chain triglyceride (LCT)50%-MCT50%)
Study: 17538537
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil containing parenteral nutrition (FO)
Study: 16842478
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mixture 25/75 (Mix 25/75)
Study: 12850677
Drug: Initial conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial conservative treatment followed by delayed laparoscopic cholecystectomy (6 to 8 weeks later)
Study: 11350436
Drug: Oral lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lithium gamolenate (700 mg daily for 15 days)
Study: 11350436
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous lithium gamolenate (0.28 g/kg)
Study: 11350436
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous lithium gamolenate (0.84 g/kg)
Study: 11350436
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous lithium gamolenate with haemolysis
Study: 9303285
Drug: Rocuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium infusion during propofol-nitrous oxide anaesthesia
Study: 9303285
Drug: Rocuronium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium infusion during isoflurane-nitrous oxide anaesthesia
Study: 8134777
Drug: Ivermectin 100
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 100 micrograms/kg single dose
Study: 29858911
Drug: Placebo (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (40 mg)
Study: 21056658
Drug: Sugar esters
Normalized name: lutein esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar esters proniosomes (SEs) for transdermal delivery of vinpocetine
Study: 21056658
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet of vinpocetine
Study: 14556923
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg per day)
Study: 14556923
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg per day)
Study: 1580636
Drug: Methionine-deprived amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine-deprived amino acid solution (AO-90)
Study: 1580636
Drug: Conventional amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional amino acid solution (control group)
Study: 3022852
Drug: C.O.P.A.C. combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.O.P.A.C. combination (Cyclophosphamide, Vincristine, Cis‐Platinum, Adriamycin and CCNU)
Study: 22146780
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for 10 weeks in addition to best medical care
Study: 18328872
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for PTSD
Study: 19005898
Drug: Torasemide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (5 mg/day) at bedtime
Study: 19005898
Drug: Torasemide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (5 mg/day) upon awakening
Study: 14571073
Drug: Medium-dose UVA1
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose UVA1 phototherapy (48 J/cm2), treated 4 times a week for 5 weeks.
Study: 8923573
Drug: Dihydroergocristine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine (2 x 3 mg/day)
Study: 31433997
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder (TIP) administered in three different daily doses as continuous or cyclical regimens for 112 days of double-blind treatment.
Study: 31433997
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in a double-blind manner for 112 days of treatment.
Study: 22228885
Drug: L-ornithine L-aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine L-aspartate (LOLA) infusion
Study: 19370275
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 mcg.kg‐1 during induction
Study: 19370275
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 mcg.kg‐1 during induction and Propofol 1 mg.kg‐1 at the end of surgery
Study: 16820557
Drug: BMC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMC group (CABG and injection of 60.10(6)+/‐31.10(6) BMC)
Study: 8147961
Drug: Zinc (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (25 mg/d)
Study: 3752487
Drug: Methohexitone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexitone (2 mg/kg)
Study: 31481323
Drug: Surgery for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery for closed ankle fractures with antibiotic prophylaxis
Study: 26328937
Drug: Water based
Normalized name: BENZOYL PEROXIDE 5% (WATER BASED) GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water based spray (control)
Study: 21051425
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL PRP (10 times higher platelet concentration than peripheral blood)
Study: 21051425
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL PRP
Study: 18444145
Drug: Tomato products
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato products (no soy) for Weeks 0 through 4, targeting a minimum of 25 mg of lycopene/day
Study: 18444145
Drug: Soy (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy (no tomatoes) for Weeks 0 through 4, providing 40 g of soy protein/day
Study: 18444145
Drug: Combined tomato-rich
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined tomato-rich diet and soy supplements for Weeks 4 through 8
Study: 10561342
Drug: Twice-daily thoracic
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily thoracic irradiation (TDTI)
Study: 10561342
Drug: Once-daily thoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily thoracic irradiation (ODTI)
Study: 1928770
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural anesthesia in combination with light general anesthesia (group 2)
Study: 27152849
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behaviour therapy (CBT) guided by a clinician for 8 weeks, comprising 8 modules of written text.
Study: 10073079
Drug: Hartmann's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hartmann's solution preloading (500 ml)
Study: 7727602
Drug: Erythropoietin 200
Normalized name: ERYTHROPOIETIN 2000 UNT/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin 200 IU/kg/day with ferric pyrophosphate 40 mg/day intravenously for 7 days before and 14 days after operation
Study: 7727602
Drug: Ferric pyrophosphate
Normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric pyrophosphate 40 mg/day alone (control group)
Study: 2024581
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy and postoperative radiotherapy
Study: 7238993
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cleansing agent)
Study: 26512604
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.125% ropivacaine + 0.3 μg/mL sufentanil
Study: 10052485
Drug: Trandolapril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (4 mg)
Study: 17566313
Drug: Verapamil-SR (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil-SR (240 mg)
Study: 17566313
Drug: Trandolapril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (4 mg) + Verapamil-SR (240 mg) combination
Study: 12911367
Drug: Diazepam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.1 mg.kg‐1
Study: 12911367
Drug: Diazepam (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (various doses: 0, 0.025, 0.5, 0.1, 0.175 mg.kg‐1)
Study: 12911367
Drug: Diazepam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.1 mg.kg‐1)
Study: 12911367
Drug: Lower diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower diazepam doses
Study: 12911367
Drug: Higher diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher diazepam doses
Study: 11138599
Drug: Conventional NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional NSAIDs (diclofenac, ibuprofen, naproxen)
Study: 8815995
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment (A) consisting of postural training, manual technique, and psychological support
Study: 8815995
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (B) using physical agents only (electrical and sonic modalities)
Study: 1357553
Drug: Corticosteroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid group (beclomethasone, 800 micrograms daily)
Study: 1357553
Drug: Anticholinergic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic group (ipratropium bromide, 160 micrograms daily)
Study: 4074611
Drug: Ultrasound administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound administration
Study: 2887192
Drug: Hydrochlorothiazide (HCTZ,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ, 25 mg day‐1)
Study: 2887192
Drug: Pindolol (PIND,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (PIND, 10 mg day‐1)
Study: 2887192
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HCTZ and PIND
Study: 29906734
Drug: Fully weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully weight-based dosing of chemotherapy (LV5FU2)
Study: 29906734
Drug: Dose-reduced chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-reduced chemotherapy
Study: 21119149
Drug: Regular recommendation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular recommendation role (antidepressant for depression, depot for schizophrenia)
Study: 21119149
Drug: Self role
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self role (treatment chosen for themselves)
Study: 18830096
Drug: Iomeprol 400
Normalized name: Iomeprol 400 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 400 (90 mL)
Study: 18830096
Drug: Iomeprol 300
Normalized name: Iomeprol 300 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 300 (120 mL)
Study: 17015530
Drug: Synchronized intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchronized intermittent mandatory ventilation plus pressure support (700-1000 g birth weight strata)
Study: 1814841
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg
Study: 1814841
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg
Study: 6383998
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous administration of vasopressin
Study: 6383998
Drug: Complications of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complications of treatment mortality
Study: 25091714
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000-U bolus intramuscularly plus 50,000 U orally weekly)